(NASDAQ: PASG) Passage Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.17%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.43%.
Passage Bio's earnings in 2025 is -$45,264,000.On average, 8 Wall Street analysts forecast PASG's earnings for 2025 to be -$34,287,155, with the lowest PASG earnings forecast at -$43,331,539, and the highest PASG earnings forecast at -$7,843,467. On average, 7 Wall Street analysts forecast PASG's earnings for 2026 to be -$16,016,884, with the lowest PASG earnings forecast at -$23,363,519, and the highest PASG earnings forecast at -$10,647,089.
In 2027, PASG is forecast to generate -$11,564,147 in earnings, with the lowest earnings forecast at -$17,538,215 and the highest earnings forecast at -$4,806,210.